African Americans more likely to exhibit negative perceptions of cancer-related clinical trials
the ONA take:
According to new findings that will be presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, researchers from Fox Chase Cancer Center and Temple University in Philadelphia, Pennsylvania, have found that African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
For the study, researchers identified 41 African Americans with an average age of 60 years. Of those, 54% had no enrolled in a clinical trial within the past 9 months.
Researchers found that non-participants believed that a clinical trial would make them sicker, that important information would be withheld from them, and that no one discussed clinical trial participation with them.
Those who participated in clinical trials felt their doctor had provided enough information in order to make an informed decisions about clinical trial participation and that trials offered the best possible treatment for their disease.
The findings suggest that African American patients with cancer should received detailed information regarding clinical trial participation and their treatment options.
African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|